Therapeutic benefits of distal ventricular pacing in mid-cavity obstructive hypertrophic cardiomyopathy
Introduction: Hypertrophic cardiomyopathy (HCM) patients with left ventricular (LV) mid-cavity obstruction (LVMCO) often experience severe drug-refractory symptoms thought to be related to intraventricular obstruction. We tested whether ventricular pacing, guided by invasive haemodynamic assessment,...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2022-08-01
|
| Series: | Therapeutic Advances in Cardiovascular Disease |
| Online Access: | https://doi.org/10.1177/17539447221108816 |
| _version_ | 1811220177031790592 |
|---|---|
| author | James W. Malcolmson Rebecca K. Hughes Abhishek Joshi Jackie Cooper Alexander Breitenstein Matthew Ginks Steffen E. Petersen Saidi A. Mohiddin Mehul B. Dhinoja |
| author_facet | James W. Malcolmson Rebecca K. Hughes Abhishek Joshi Jackie Cooper Alexander Breitenstein Matthew Ginks Steffen E. Petersen Saidi A. Mohiddin Mehul B. Dhinoja |
| author_sort | James W. Malcolmson |
| collection | DOAJ |
| description | Introduction: Hypertrophic cardiomyopathy (HCM) patients with left ventricular (LV) mid-cavity obstruction (LVMCO) often experience severe drug-refractory symptoms thought to be related to intraventricular obstruction. We tested whether ventricular pacing, guided by invasive haemodynamic assessment, reduced LVMCO and improved refractory symptoms. Methods: Between December 2008 and December 2017, 16 HCM patients with severe refractory symptoms and LVMCO underwent device implantation with haemodynamic pacing study to assess the effect on invasively defined LVMCO gradients. The effect on the gradient of atrioventricular (AV) synchronous pacing from sites including right ventricular (RV) apex and middle cardiac vein (MCV) was retrospectively assessed. Results: Invasive haemodynamic data were available in 14 of 16 patients. Mean pre-treatment intracavitary gradient was 77 ± 22 mmHg (in sinus rhythm) versus 21 ± 21 mmHg during pacing from optimal ventricular site (95% CI: −70.86 to −40.57, p < 0.0001). Optimal pacing site was distal MCV in 12/16 (86%), RV apex in 1/16 and via epicardial LV lead in 1/16. Pre-pacing Doppler-derived gradients were significantly higher than at follow-up (47 ± 15 versus 24 ± 16 mmHg, 95% CI: −37.19 to −13.73, p < 0.001). Median baseline NYHA class was 3, which had improved by ⩾1 NYHA class in 13 of 16 patients at 1-year post-procedure ( p < 0.001). The mean follow-up duration was 4.6 ± 2.7 years with the following outcomes: 8/16 (50%) had continued symptomatic improvement, 4/16 had symptomatic decline and 4/16 died. Contributors to symptomatic decline included chronic atrial fibrillation (AF) ( n = 5), phrenic nerve stimulation ( n = 3) and ventricular ectopy ( n = 1). Conclusion: In drug-refractory symptomatic LVMCO, distal ventricular pacing can reduce intracavitary obstruction and may provide long-term symptomatic relief in patients with limited treatment options. A haemodynamic pacing study is an effective strategy for identifying optimal pacing site and configuration. |
| first_indexed | 2024-04-12T07:37:05Z |
| format | Article |
| id | doaj.art-c0e53ade35c54256830cab7e51250a35 |
| institution | Directory Open Access Journal |
| issn | 1753-9455 |
| language | English |
| last_indexed | 2024-04-12T07:37:05Z |
| publishDate | 2022-08-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Cardiovascular Disease |
| spelling | doaj.art-c0e53ade35c54256830cab7e51250a352022-12-22T03:41:54ZengSAGE PublishingTherapeutic Advances in Cardiovascular Disease1753-94552022-08-011610.1177/17539447221108816Therapeutic benefits of distal ventricular pacing in mid-cavity obstructive hypertrophic cardiomyopathyJames W. MalcolmsonRebecca K. HughesAbhishek JoshiJackie CooperAlexander BreitensteinMatthew GinksSteffen E. PetersenSaidi A. MohiddinMehul B. DhinojaIntroduction: Hypertrophic cardiomyopathy (HCM) patients with left ventricular (LV) mid-cavity obstruction (LVMCO) often experience severe drug-refractory symptoms thought to be related to intraventricular obstruction. We tested whether ventricular pacing, guided by invasive haemodynamic assessment, reduced LVMCO and improved refractory symptoms. Methods: Between December 2008 and December 2017, 16 HCM patients with severe refractory symptoms and LVMCO underwent device implantation with haemodynamic pacing study to assess the effect on invasively defined LVMCO gradients. The effect on the gradient of atrioventricular (AV) synchronous pacing from sites including right ventricular (RV) apex and middle cardiac vein (MCV) was retrospectively assessed. Results: Invasive haemodynamic data were available in 14 of 16 patients. Mean pre-treatment intracavitary gradient was 77 ± 22 mmHg (in sinus rhythm) versus 21 ± 21 mmHg during pacing from optimal ventricular site (95% CI: −70.86 to −40.57, p < 0.0001). Optimal pacing site was distal MCV in 12/16 (86%), RV apex in 1/16 and via epicardial LV lead in 1/16. Pre-pacing Doppler-derived gradients were significantly higher than at follow-up (47 ± 15 versus 24 ± 16 mmHg, 95% CI: −37.19 to −13.73, p < 0.001). Median baseline NYHA class was 3, which had improved by ⩾1 NYHA class in 13 of 16 patients at 1-year post-procedure ( p < 0.001). The mean follow-up duration was 4.6 ± 2.7 years with the following outcomes: 8/16 (50%) had continued symptomatic improvement, 4/16 had symptomatic decline and 4/16 died. Contributors to symptomatic decline included chronic atrial fibrillation (AF) ( n = 5), phrenic nerve stimulation ( n = 3) and ventricular ectopy ( n = 1). Conclusion: In drug-refractory symptomatic LVMCO, distal ventricular pacing can reduce intracavitary obstruction and may provide long-term symptomatic relief in patients with limited treatment options. A haemodynamic pacing study is an effective strategy for identifying optimal pacing site and configuration.https://doi.org/10.1177/17539447221108816 |
| spellingShingle | James W. Malcolmson Rebecca K. Hughes Abhishek Joshi Jackie Cooper Alexander Breitenstein Matthew Ginks Steffen E. Petersen Saidi A. Mohiddin Mehul B. Dhinoja Therapeutic benefits of distal ventricular pacing in mid-cavity obstructive hypertrophic cardiomyopathy Therapeutic Advances in Cardiovascular Disease |
| title | Therapeutic benefits of distal ventricular pacing in mid-cavity obstructive hypertrophic cardiomyopathy |
| title_full | Therapeutic benefits of distal ventricular pacing in mid-cavity obstructive hypertrophic cardiomyopathy |
| title_fullStr | Therapeutic benefits of distal ventricular pacing in mid-cavity obstructive hypertrophic cardiomyopathy |
| title_full_unstemmed | Therapeutic benefits of distal ventricular pacing in mid-cavity obstructive hypertrophic cardiomyopathy |
| title_short | Therapeutic benefits of distal ventricular pacing in mid-cavity obstructive hypertrophic cardiomyopathy |
| title_sort | therapeutic benefits of distal ventricular pacing in mid cavity obstructive hypertrophic cardiomyopathy |
| url | https://doi.org/10.1177/17539447221108816 |
| work_keys_str_mv | AT jameswmalcolmson therapeuticbenefitsofdistalventricularpacinginmidcavityobstructivehypertrophiccardiomyopathy AT rebeccakhughes therapeuticbenefitsofdistalventricularpacinginmidcavityobstructivehypertrophiccardiomyopathy AT abhishekjoshi therapeuticbenefitsofdistalventricularpacinginmidcavityobstructivehypertrophiccardiomyopathy AT jackiecooper therapeuticbenefitsofdistalventricularpacinginmidcavityobstructivehypertrophiccardiomyopathy AT alexanderbreitenstein therapeuticbenefitsofdistalventricularpacinginmidcavityobstructivehypertrophiccardiomyopathy AT matthewginks therapeuticbenefitsofdistalventricularpacinginmidcavityobstructivehypertrophiccardiomyopathy AT steffenepetersen therapeuticbenefitsofdistalventricularpacinginmidcavityobstructivehypertrophiccardiomyopathy AT saidiamohiddin therapeuticbenefitsofdistalventricularpacinginmidcavityobstructivehypertrophiccardiomyopathy AT mehulbdhinoja therapeuticbenefitsofdistalventricularpacinginmidcavityobstructivehypertrophiccardiomyopathy |